Epcoritamab Maintenance and Quality of Life Considerations in Follicular Lymphoma

EP: 1.Introduction and Exploring the Financial Burden of Follicular Lymphoma

EP: 2.Optimizing First- and Second-Line Treatment Strategies in Follicular Lymphoma

EP: 3.Advancing Care in Relapsed/Refractory Follicular Lymphoma Beyond Chemotherapy

EP: 4.Integrating Bispecific Antibodies and Evolving Strategies in Relapsed/Refractory Follicular Lymphoma

EP: 5.Implications of the RELEVANCE Study and Optimal Use of R² in Second-Line Follicular Lymphoma

EP: 6.Targeted Therapies and Bispecific Antibodies in Second-Line Follicular Lymphoma

Now Viewing

EP: 7.Epcoritamab Maintenance and Quality of Life Considerations in Follicular Lymphoma

Recent analyses evaluating epcoritamab maintenance therapy have demonstrated promising efficacy in sustaining responses in patients with follicular lymphoma, suggesting that extended treatment can help prolong disease control in the relapsed/refractory setting. These findings are likely to influence clinical practice by supporting earlier integration of maintenance strategies for suitable patients while balancing long-term tolerability. Quality of life (QoL) is a critical consideration, as follicular lymphoma and its treatments can impact fatigue, physical functioning, emotional well-being, and social engagement. Incorporating patient-reported outcomes and proactive supportive care helps mitigate these challenges. In studies comparing epcoritamab plus rituximab and lenalidomide (R²) versus R² alone, QoL measures were maintained or improved, highlighting that adding epcoritamab does not compromise—and may even enhance—patients’ overall well-being. These results reinforce the potential of novel immunotherapies to achieve both clinical efficacy and meaningful patient-centered benefits.